Skip to main content

ccRCC

2
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Medpace
MedpaceCINCINNATI, OH
1 program
1
177Lu-TLX250Phase 31 trial
Active Trials
NCT07197580Recruiting40Est. Feb 2029
Telix Pharmaceuticals
Telix PharmaceuticalsAustralia - Brisbane
1 program
1
177Lu-TLX250Phase 3
NiKang Therapeutics
NiKang TherapeuticsDE - Wilmington
2 programs
Oral NKT2152PHASE_1_21 trial
NKT2152PHASE_21 trial
Active Trials
NCT05119335Terminated120Est. Sep 2025
NCT05935748Terminated18Est. Sep 2025
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Visceral Fat Area as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma: A Multicenter Study N/A1 trial
Active Trials
NCT06791863Completed1,030Est. Sep 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Medpace177Lu-TLX250
NiKang TherapeuticsNKT2152
NiKang TherapeuticsOral NKT2152
UNION therapeuticsVisceral Fat Area as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma: A Multicenter Study

Clinical Trials (4)

Total enrollment: 1,208 patients across 4 trials

NCT07197580Medpace177Lu-TLX250

Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

Start: Mar 2026Est. completion: Feb 202940 patients
Phase 3Recruiting
NCT05935748NiKang TherapeuticsNKT2152

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Start: Jul 2023Est. completion: Sep 202518 patients
Phase 2Terminated
NCT05119335NiKang TherapeuticsOral NKT2152

A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Start: Oct 2021Est. completion: Sep 2025120 patients
Phase 1/2Terminated
NCT06791863UNION therapeuticsVisceral Fat Area as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma: A Multicenter Study

Visceral Fat Area as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma: A Multicenter Study on Postoperative Survival

Start: Nov 2014Est. completion: Sep 20231,030 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,208 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.